The findings presented in this report demonstrate effectiveness of exogenous ARSB on inhibition of the progression of subcutaneous mouse melanomas and elucidate mechanisms which lead to declines in matrix metalloproteinases 2 and 9 and chondroitin sulfate proteoglycan 4, known biomarkers of melanoma progression. This evidence concerns the gene MMP2 and melanoma.